Hims & Hers (HIMS) shares rallied another 6% in premarket today after Eli Lilly (LLY) warned of health risks from impurity it discovered in the compounded version of its weight-loss drug.
This helped HIMS push higher as the company just announced a truce and partnership with Ozempic- and Wegovy-maker Novo Nordisk (NVO), reinforcing its transition from a high-risk “gray market” pharmacy to a legitimate, sanctioned distribution partner for Big Pharma.
Him & Hers stock is now up nearly 90% versus the start of March, an explosive rally that warrants intense scrutiny before starting a new position.
Should You Invest in Hims & Hers Stock Today?
While the NVO deal eliminates a major regulatory overhang on HIMS shares, profitability metrics present a more cautious picture for potential investors in 2026.
The telehealth firm ended Q4 with negative free cash flow and $1 billion in convertible debt, which raises questions about its financial flexibility despite operational momentum.
Meanwhile, capital expenditures more than doubled to roughly $243 million, driven by pharmacy automation investments that are broadly expected to burden near-term cash generation.
Hims & Hers' relative strength index (14-day) has climbed into overbought territory as well, further signaling potential for a near-term correction.
HIMS Shares Are Trading at a Premium Currently
Investors are cautioned against chasing the momentum in Hims & Hers shares as selling branded drugs at Novo’s self-pay prices will likely generate lower margins than compounded alternatives. This transition, while strategically sound for removing regulatory risk, creates near-term headwinds for profitability that may compress valuation if execution falters.
Moreover, HIMS is now trading at a forward price-to-earnings (P/E) multiple of about 42x, which appears rather stretched for a company that faces intense competition in the telehealth landscape.
Geopolitical headwinds present an underappreciated risk as well. Rising oil prices and Middle East tensions have started pressuring stock prices, and a sustained risk-off environment may overwhelm positive catalysts specific to the telehealth sector.
How Wall Street Recommends Playing Hims & Hers
Wall Street analysts seem to agree that the recent Hims & Hers rally has indeed gone a bit too far.
The consensus rating on HIMS shares sits at a “Hold” only, with the mean price target of about $24.42 indicating potential downside roughly 10% from here.
This article was created with the support of automated content tools from our partners at Sigma.AI. Together, our financial data and AI solutions help us to deliver more informed market headline analysis to readers faster than ever.
On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
- Dear Lucid Motors Stock Fans, Mark Your Calendars for March 12
- Billionaire Leo KoGuan Now Owns 2 MILLION Shares of Nvidia Stock. Should You Back Up the Truck and Buy Too?
- This Under-the-Radar Stock Has Surged 1,300% Over the Past Year
- Will SoFi Become a $30 Stock Again or Keep Languishing Below $20?
